Patents Assigned to Zonagen, Inc.
  • Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
    Publication number: 20040171697
    Abstract: The present invention discloses compositions and methods useful for treating wasting, especially a loss of muscle mass. The present invention also discloses compositions and methods useful for treating lipodystrophy. The compositions and methods of the present invention are particularly beneficial to HIV-infected individuals.
    Type: Application
    Filed: November 12, 2003
    Publication date: September 2, 2004
    Applicant: ZONAGEN, INC.
    Inventors: Joseph S. Podolski, Ronald Wiehle
  • Methods for treatment of erectile dysfunction
    Publication number: 20040102475
    Abstract: Improved drug compositions and methods useful in the treatment of male erectile dysfunction. An optimized mixture of the drugs phentolamine mesylate, papaverine hydrochloride, and alprostadil in a buffer containing L-arginine and glycine is to be injected into the penile tissue to produce an erection in otherwise impotent men.
    Type: Application
    Filed: November 3, 2003
    Publication date: May 27, 2004
    Applicant: ZONAGEN, INC.
    Inventor: Joseph S. Podolski
  • Methods and compositions with trans-clomiphene
    Publication number: 20040097597
    Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism. The present invention is also directed to methods of decreasing cholesterol levels.
    Type: Application
    Filed: April 30, 2003
    Publication date: May 20, 2004
    Applicant: Zonagen, Inc.
    Inventors: Joseph S. Podolski, Ronald Wiehle
  • Methods for treatment of male erectile dysfunction
    Patent number: 6696072
    Abstract: Improved drug compositions and methods useful in the treatment of male erectile dysfunction. An optimized mixture of the drugs phentolamine mesylate, papaverine hydrochloride, and alprostadil in a buffer containing L-arginine and glycine is to be injected into the penile tissue to produce an erection in otherwise impotent men.
    Type: Grant
    Filed: January 31, 2000
    Date of Patent: February 24, 2004
    Assignee: Zonagen, Inc.
    Inventor: Joseph S. Podolski
  • Combination therapy for modulating the human sexual response
    Publication number: 20030207891
    Abstract: The invention is directed to compositions and methods for modulating the human sexual response. The compositions comprise two or more pharmaceutically active agents which preferably include an alpha-adrenergic antagonist and a phosphodiesterase inhibitor.
    Type: Application
    Filed: June 17, 2003
    Publication date: November 6, 2003
    Applicant: Zonagen, Inc.
    Inventor: Joseph S. Podolski
  • Combination therapy for modulating the human sexual response
    Publication number: 20030004170
    Abstract: The invention is directed to compositions and methods for modulating the human sexual response. The compositions comprise two or more pharmaceutically active agents which preferably include an alpha-adrenergic antagonist and a phosphodiesterase inhibitor.
    Type: Application
    Filed: August 13, 2002
    Publication date: January 2, 2003
    Applicant: ZONAGEN, INC.
    Inventor: Joseph S. Podolski
  • Compositions for the treatment of male erectile dysfunction
    Patent number: 6482426
    Abstract: Improved drug compositions and methods useful in the treatment of male erectile dysfunction. An optimized mixture of the drugs phentolamine mesylate, papaverine hydrochloride, and alprostadil in a buffer containing L-arginine and glycine is to be injected into the penile tissue to produce an erection in otherwise impotent men.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: November 19, 2002
    Assignee: Zonagen, Inc.
    Inventor: Joseph S. Podolski
  • Methods and materials for the treatment of prostatic carcinoma
    Patent number: 6280742
    Abstract: The present invention related generally to materials and methods for reduction and/or alleviation of prostatic and prostatic-related (metatastic) carcinoma via the administration of disclosed compositions, immunotherapeutic agents, or antibodies.
    Type: Grant
    Filed: June 17, 1998
    Date of Patent: August 28, 2001
    Assignee: Zonagen, Inc.
    Inventors: Christopher Allen Seid, Gurpreet Singh
  • Method of preparation and use for zona pellucida antigens and antibodies for sterilization and contraception
    Patent number: 6264953
    Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in an individual which will bind to epitopes on zona pellucida. Also disclosed are immunogenic compositions and methods for immunizing an individual to enable the production of antibodies to zona pellucida antigens. Also disclosed are the use of these recombinant molecules and monoclonal antibodies thereto for immunocontraception or sterilization.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: July 24, 2001
    Assignee: Zonagen, Inc.
    Inventor: Bonita Sue Dunbar
  • Methods and formulations for modulating the human sexual response
    Patent number: 6166061
    Abstract: The invention is directed to oral formulations of the vasodilator phentolamine to modulate sexual response on demand.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: December 26, 2000
    Assignee: Zonagen, Inc.
    Inventor: Fred Lowrey
  • Methods and formulations for modulating the human sexual response
    Patent number: 6124337
    Abstract: The invention is directed to improved methods for modulating the human sexual response by orally administering a formulation comprising phentolamine and thereby modulating the sexual response on demand.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: September 26, 2000
    Assignee: Zonagen, Inc.
    Inventor: Fred Lowrey
  • Methods and formulations for modulating the human sexual response
    Patent number: 6100286
    Abstract: The invention is directed to improved methods for modulating the human sexual response by administering an oral formulation of phentolamine to the blood circulation thereby modulating the sexual response on demand.
    Type: Grant
    Filed: March 10, 1998
    Date of Patent: August 8, 2000
    Assignee: Zonagen, Inc.
    Inventor: Fred Lowrey
  • Methods and formulations for modulating the human sexual response
    Patent number: 6051594
    Abstract: The invention is directed to improved methods for modulating the human sexual response by orally administering a formulation of the vasodilator phentolamine to the blood circulation and thereby modulating the sexual response on demand.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: April 18, 2000
    Assignee: Zonagen, Inc.
    Inventor: Fred Lowrey
  • Materials and methods for immunocontraception
    Patent number: 6027727
    Abstract: A method for specifically inducing transient infertility or permanent sterility in a host animal by selective vaccination with specific zona pellucida proteins or immunocontraceptively active fragments thereof. Novel zona pellucida DNA sequences encoding specific zona pellucida proteins are disclosed.
    Type: Grant
    Filed: November 9, 1993
    Date of Patent: February 22, 2000
    Assignee: Zonagen, Inc.
    Inventors: Jeffrey D. Harris, Kuang T. Hsu, Joseph S. Podolski
  • DNAs encoding mammalian ZPBs
    Patent number: 6001599
    Abstract: A method for specifically inducing transient infertility or permanent sterility in a host animal by selective vaccination with specific zona pellucida proteins or immunocontraceptively active fragments thereof. Novel zona pellucida DNA sequences encoding specific zona pellucida proteins are disclosed.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 14, 1999
    Assignee: Zonagen, Inc.
    Inventors: Jeffrey D. Harris, Kuang T. Hsu, Joseph S. Podolski
  • Materials and methods for immunocontraception
    Patent number: 5989550
    Abstract: A method for specifically inducing transient infertility or permanent sterility in a host animal by selective vaccination with specific zona pellucida proteins or immunocontraceptively active fragments thereof. Novel zona pellucida DNA sequences encoding specific zona pellucida proteins are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 23, 1999
    Assignee: Zonagen, Inc.
    Inventors: Jeffrey D. Harris, Kuang T. Hsu, Joseph S. Podolski
  • Mammalian ZPAs
    Patent number: 5981228
    Abstract: A method for specifically inducing transient infertility or permanent sterility in a host animal by selective vaccination with specific zona pellucida proteins or immunocontraceptively active fragments thereof. Novel zona pellucida DNA sequences encoding specific zona pellucida proteins are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 9, 1999
    Assignee: Zonagen, Inc.
    Inventors: Jeffrey D. Harris, Kuang T. Hsu, Joseph S. Podolski
  • Methods and formulations for modulating the human sexual response
    Patent number: 5981563
    Abstract: The invention is directed to improved methods for modulating the human sexual response by orally administering a rapidly dissolving tablet comprising phentolamine or its pharmaceutically acceptable salts to the blood circulation, thereby modulating the sexual response on demand.
    Type: Grant
    Filed: October 29, 1997
    Date of Patent: November 9, 1999
    Assignee: Zonagen, Inc.
    Inventor: Fred Lowrey
  • Chitosan induced immunopotentiation
    Patent number: 5980912
    Abstract: Methods and compositions for potentiating an immune response are disclosed which incorporate chitosan as an immunopotentiating adjuvant. Administration of the compositions of the invention is effected by various routes.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: November 9, 1999
    Assignee: Zonagen, Inc.
    Inventors: Joseph S. Podolski, Mitzi L. Martinez
  • ZPC polypeptides
    Patent number: 5976545
    Abstract: A method for specifically inducing transient infertility or permanent sterility in a host animal by selective vaccination with specific zona pellucida proteins or immunocontraceptively active fragments thereof. Novel zona pellucida DNA sequences encoding specific zona pellucida proteins are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 2, 1999
    Assignee: Zonagen, Inc.
    Inventors: Jeffrey D. Harris, Kuang T. Hsu, Joseph S. Podolski